Triplepoint Venture Growth (TPVG)

Overall impact
D (28)

Commentary

Triplepoint Venture Growth is a below-average overall performer. With a 'D' rating of 28.1 for overall impact (bottom 25% of all companies), Triplepoint Venture Growth ranks 25th out of 27 industry peers, behind PhenixFIN, B&M European Value Retail, Kayne Anderson and 21 others, and ahead of KPS Capital Partners and Bayside Capital. On top material causes for Triplepoint Venture Growth's industry (Financial Services), Triplepoint Venture Growth performs poorly in Fair Labor Practices (25.3 score), Healthy Oceans (35.1), Accountable Institutions (9.5) and 14 other causes where it received a 'D' or 'F' score. Triplepoint Venture Growth did not receive an 'A' rating on any cause.
Impact
Cause TPVG
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
2013
Sector
Financials
Industry
Capital Markets
Sub-industry
Investment Banking & Brokerage
SASB industry
Asset Management & Custody Activities
Headquarters
Ca, United States
Share classes
TPVG
Description
TriplePoint Venture Growth BDC Corp. is a business development company specializing investments in venture capital-backed companies at the growth stage investments. It also provides debt financing to venture growth space companies which includes growth capital loans, secured and customized loans, equipment financings, revolving loans and direct equity investments. The fund seeks to invest in e-commerce, entertainment, technology and life sciences sector. Within technology the areas of focus include: Security, wireless communication equipments, network system and software, business applications software, conferencing equipments/services .big data, cloud computing, data storage, electronics, energy efficiency, hardware, information services, internet and media, networking, semiconductors, software, software as a service, and other technology related subsectors and within life sciences the areas of focus include: biotechnology, bio fuels/bio mass, diagnostic testing and bioinformatics, drug delivery, drug discovery, healthcare information systems, healthcare services, medical, surgical and therapeutic devices, pharmaceuticals and other life science related subsectors. Within growth capital loans it invests between $5 million and $50 million, for equipment financings it invests between $5 million and $25 million, for revolving loans it invests between $1 million and $25 million, and for direct equity investments it may invest between $0.1 million and $5 million (generally not exceeding 5% of the company's total equity). The debt financing products are typically structured as lines of credit and it invests through warrants and secured loans. It targeted returns between 10% and 18%. It does not take board seat in the company.
Material causes
Ethos considers the following causes material for Triplepoint Venture Growth, based on its industry sub-industry Investment Banking & Brokerage. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.